舒肝解郁胶囊在ⅢB型前列腺炎相关性功能障碍综合治疗中的疗效评价

发布时间：2017-12-28 21:09

本文关键词：舒肝解郁胶囊在ⅢB型前列腺炎相关性功能障碍综合治疗中的疗效评价　出处：《中华男科学杂志》2015年06期 　论文类型：期刊论文

【摘要】：目的:探讨α-受体阻断剂联合舒肝解郁胶囊治疗ⅢB型前列腺炎伴性功能障碍的临床疗效。方法:将98例ⅢB型前列腺炎伴性功能障碍患者随机分为对照组和治疗组,每组49例。对照组给予α-受体阻断剂盐酸坦洛新缓释胶囊、生物反馈技术治疗及前列腺按摩;治疗组在给予α-受体阻断剂盐酸坦洛新缓释胶囊、生物反馈技术治疗的同时,口服舒肝解郁胶囊;两组均治疗2周为1个疗程,连续治疗8周。治疗前后两组分别应用美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)测评症状严重程度,用国际勃起功能指数-5(IIEF-5)和早泄评分指数-5(CIPE-5)测评患者性功能状况,同时用汉密尔顿焦虑量表(HAMA)和汉密尔顿抑郁量表(HAMD)测评患者焦虑、抑郁等情绪障碍状况,并对各项结果进行统计学分析。结果:治疗后8周,对照组NIH-CPSI为(26.31±7.91)分,治疗组为(18.84±6.63)分,差异有显著性(P0.01);对照组CIPE-5为(10.41±3.037)分,治疗组为(14.37±2.35)分,差异有显著性(P0.05);对照组IIEF-5为(10.29±3.97)分,治疗组为(14.69±4.19)分,差异有显著性(P0.05);对照组HAMA为(24.31±1.78)分,而治疗组为(13.41±4.21)分,差异有显著性(P0.01),同时对照组HAMD为(25.24±2.83)分,而治疗组为(14.49±4.44)分,差异有显著性(P0.01)。结论:舒肝解郁胶囊能缓解患者的焦虑、抑郁心理状态,进而改善慢性前列腺炎患者的躯体症状以及勃起功能和早泄症状,是治疗ⅢB型前列腺炎伴性功能障碍的有效药物。
[Abstract]:Objective: To investigate the clinical effect of alpha receptor blocking agent combined with Shuganjieyu capsule in treatment of type B prostatitis. Methods: 98 cases of type III B prostatitis with sexual dysfunction were randomly divided into the control group and the treatment group, with 49 cases in each group. The control group was given alpha blockers Tamsulosin Hydrochloride Sustained-release Capsules, biofeedback treatment and massage of the prostate; in the treatment group were given alpha blockers Tamsulosin Hydrochloride Sustained-release Capsules, biofeedback treatment, oral Shuganjieyu capsule; two groups were treated for 2 weeks as 1 course of treatment, continuous treatment for 8 weeks. The two groups before and after treatment respectively with the National Institutes of Health Chronic Prostatitis Symptom Score (NIH-CPSI) assessment of the severity of symptoms, with the international index of erectile function (IIEF-5) and -5 -5 (CIPE-5) score index of premature ejaculation sexual dysfunction in patients with evaluation, at the same time with the Hamilton anxiety scale (HAMA) and Hamilton Depression Scale (HAMD) assessment patients with anxiety and depression disorder, and the results were statistically analyzed. Results: after 8 weeks of treatment, the control group NIH-CPSI (26.31 + 7.91), treatment group (18.84 + 6.63), there was significant difference (P0.01); group CIPE-5 (10.41 + 3.037), treatment group (14.37 + 2.35), there was significant difference (P0.05) the control group; IIEF-5 (10.29 + 3.97), treatment group (14.69 + 4.19), there was significant difference (P0.05); group HAMA (24.31 + 1.78), and the treatment group (13.41 + 4.21), there was significant difference (P0.01), the control group is HAMD at the same time (25.24 + 2.83), and the treatment group (14.49 + 4.44), there was significant difference (P0.01). Conclusion: Shuganjieyu capsule can relieve the anxiety and depression status of patients and improve the patients with chronic prostatitis symptoms and symptoms of premature ejaculation and erectile function, is an effective drug for the treatment of type B prostatitis.
【作者单位】：赤峰学院附属医院临床心理科;赤峰学院附属医院泌尿外科;
【基金】：国家自然科学基金(81260196;81450036)~~
【分类号】：R697.33
【正文快照】： Supported by grants from National Natural Science Foundation of China(81260196,81450036).Correspondence to:XIA Hai-bo,email:haiboxia8060101@163.comReceived:November 3,2014;accepted:March 17,2015慢性前列腺炎是中青年男性的常见病和难治病,约50%的男性在一生中

【参考文献】